Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy (c diff)
Recruitment status was: Recruiting
|First Received Date ICMJE||November 14, 2011|
|Last Updated Date||June 11, 2012|
|Start Date ICMJE||December 2011|
|Estimated Primary Completion Date||December 2014 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Cessation of GI symptoms: nausea, bloating, pain, constipation or diarrhea, vomiting, weight loss, [ Time Frame: 2 weeks ]|
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01472978 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy|
|Official Title ICMJE||Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy|
|Brief Summary||The investigators found that community acquired C. diff occurs in children undergoing a colonoscopy. When they were treated their symptoms got better. But, the investigators do not know if the treatment for the C. diff made them better or another other factor made them feel better. So, the investigators designed the following study. Children undergoing a colonoscopy who are found to be C. diff positive at the time of the colonoscopy are randomized to one group that gets immediate treatment or a second group that gets delayed treatment. Both groups are closely monitored for symptoms.|
Clostridium difficile (CD) is a gram positive, spore forming anaerobic bacillus that is not a normal commensal of the gastrointestinal tract. It was initially named "difficult clostridium" because it was difficult to isolate and grow on culture media. CD can exist in spore and vegetative forms. Outside the colon, it survives in a spore form that is resistant to heat, acid and antibiotics. In the colon, CD is found in the vegetative, toxin-producing form and is susceptible to antibiotics. CD is widely distributed and infection is acquired through the fecal-oral route from person to person contact, although the organism can be cultured from toilets, bedpans, floors, telephones, shoes of hospital personnel and other items. CD is most often identified as a disease acquired from medical facilities, but community-acquired CD (CACD) is also described. CD infection is positively associated with the use of antibiotics and gastric acid suppressing agents. CD infection is described in patients who have inflammatory bowel disease and is significantly associated with their need for hospitalization. Those who are hospitalized for inflammatory bowel disease and CD have higher mortality and longer hospital stays than patients with inflammatory bowel disease but no CD infection.
CD is a serious problem among adults. Less is known about CD in children. Although CD was first identified in newborns, it is not considered a pathogen in children less than one year of age. In older children CD causes a spectrum of disease similar to that seen in adults but at a lower rate and with less severity. The epidemiology of CD in children has not been studied extensively or in a systematic manner. However, intestinal colonization occurs in 5% of all children older than 2 years of age. Recently, the investigators found colonic aspirates positive for CD toxin from children at the time of their colonoscopies and in whom CD was not suspected.
Our retrospective chart review of children undergoing colonoscopy from 9/1/2006 through 8/30/2008 identified 41 (17%) CD positive colonic aspirates. There was no difference between CD positive and negative patients except abdominal pain and weight loss together occurred significantly more often in the CD positive group. Significantly more CD positive patients (p = 0.01) used an H2RA within one month of colonoscopy. Too few patient charts contained information on antibiotic use to determine if a relationship existed with CD. Of the CD positive patients 5 were lost to follow up, 36 were treated and all except 1 patient had resolution of symptoms. The investigators concluded that CD infection, likely acquired in the community, is common in children undergoing a colonoscopy and symptoms cannot be used to discriminate which children will be positive for CD.
The investigators also cultured patient care sites at Women and Children's Hospital and found no CD contamination of colonoscopes, medical areas, or supplies was identified. Colonic aspirates were obtained from 73% of colonoscopies.
This retrospective chart review had several weaknesses. The most important weakness is that the study design did not allow us to discriminate between intestinal colonization that occurs in 5% of all children (15) older than 2 years of age or infection. The study did not permit an assessment of whether treatment had a significant effect on the symptoms for which the children presented because there was no control group. The investigators address these weaknesses in this prospective study.
d. Experimental or Study Design: i. Brief: Double blind crossover study with a control arm. ii. Detailed: Patients undergoing colonoscopy will be screened at time of initial recruitment for exclusion criteria. At time of endoscopy a stool aspirate culture (routine) will be collected. At time of endoscopy patients will be subjected to a second round of exclusion criteria based on visual findings. Patients with CD (+) stool by aspirate will be randomized into one of two treatment arms (early, delay). In addition, a third arm of CD (-) age match controls will also be followed.
e. Sample Size i. A power calculation performed by Chang-Xing Ma PhD. based on an improvement in symptoms of 1 point between groups on pain scale was performed. Recruiting 25 patients to each sample group and assuming a 30% drop out rate, final group sample sizes of 17 and 17 achieve 80.7% power to detect a difference of 1.0 between two group means with estimated group standard deviations of 1.0 and 1.0 and with a significance level (alpha) of 0.05000 using a two-sided two-sample t-test.
ii. Based on the data from the retrospective review the investigators know that there is a large amount of variability in this population and expect 1-2 patients enrolled per month.
f. Variables of Interest i. Subjective: nausea, bloating, ii. Objective: pain, stool frequency, stool consistency, vomiting, weight loss, antibiotic use, use of acid suppression iii. Biochemical: stool glutamate dehydrogenase, lactoferrin, CD culture, CD toxin
g. Completion i. Recruitment period: 18 months ii. Completion of therapy after recruitment: 1 month iii. Data analysis: 1 month iv. Total anticipated duration: 2 years
B. Characteristics of the Research Population
i. Any gender ii. Any race iii. Age between 7-21 iv. Greater then 21 kg v. Able to swallow pills e. Exclusion Criteria (at time of screening): i. marked abdominal tenderness and distention with minimal diarrhea ii. history of inflammatory bowel disease iii. fever iv. systemic toxicity v. allergy to metronidazole vi. short bowel syndrome vii. history of bowel resection viii. history of abdominal surgery (excluding appendectomy or cholecystectomy) ix. history of hirschsprungs disease x. active pregnancy xi. inability to participate in phone surveys xii. inability to maintain scheduled clinic follow up xiii. bloody stools at time of screening f. Exclusion Criteria (at time of colonoscopy) i. Visual evidence of pseudomembranes ii. Visible ulcerations iii. Mucosal friability iv. Mayo score greater than 4 v. Fissures/fistulas
g. Vulnerable Subjects- The impact of chronic abdominal pain is noted to have a high prevalence, strong health care use, and considerable restrictions in the daily life of children and Adolescents (16, 17). As a result of this disease burden it is prudent to study this vulnerable population to determine if a biological trigger is present, and if present how can this trigger be monitored and treated. To protect this population in this investigation all patients participating under the age of 18 will be required to have both a parental consent and a participant assent. Patients older than 18 years of age will be required to have a documented consent. Participation in the project is voluntary and permission to participate may be withdrawn at any time without risk of changing accepted standard of care. All tests and procedures are non-invasive, and monetary reward for completion of study is sufficient to compensate for time and travel costs so not to incur a financial burden on the family, in addition the monies is not so great as to encourage participation for the sake of monetary gain.
C. Methods and Procedures
a. Recruitment and enrollment methods i. Patients will be recruited from the Department of Pediatrics, Digestive Disease and Nutrition Center. The patient population of interest does not necessitate recruitment of patients outside of the normal scope of practice ii. Enrollment will be voluntary. Eligible patients will be screened at time of clinic visit and offered the potential opportunity to participate in the study pending the results of routine screening.
iii. Patients who fulfill inclusion/exclusion criteria at the end of initial screening and have self identified themselves as interested in participation will be given the opportunity to participate in the study.
b. Privacy Protection i. See Section C part e and f.
c. Research Setting i. Women and Children's Hospital of Buffalo and allied clinics
d. Summary of Research Design i. See Section A part d.
e. Randomization i. Group assignment will be assigned at time of colonoscopy ii. Group assignment will be in place for those patients assigned to a therapeutic intervention iii. Random group assignment list by patient enrollment number was generated by Chang-Xang Ma, PhD
f. HIPAA i. The patients "Informed Consent Form" (please see section 6 of application) will be accompanied by a separate document incorporating Health Insurance Portability and Accountability Act (HIPAA) compliant wording by which patients/parents/legal guardian authorize the use and disclosure of their Protected Health information by the investigator and by those persons who need that information for the purposes of the study.
The Written Informed Consent will explain that for data verification purposes, study personnel, a regulatory authority, or an IRB may require direct access to parts of the hospital or practice records relevant to the study, including patients' medical history.
g. Data Storage and Confidentiality i. All study data will be securely housed at the Digestive Disease and Nutrition Center located at 219 Bryant Street ii. All electronic data is securely housed in Cerner Powerchart monitored by Kaleida Health
h. Payments/compensation i. Patients will be compensated $60.00 at the completion of the study
i. Data Analysis Plan i. Statistical analysis will be performed by a professional statistician, Chang-Xang Ma, PhD, at the University at Buffalo, Buffalo, NY. Comparisons treatment 1 and treatment 2 groups will be performed by SAS statistical software using chi square, Fisher's exact tests, t-test and multivariate analysis as indicated.
D. Risks and Potential Benefits of Participation in the Research a. Subject Risk i. The risk to subjects for the initial colonoscopy is no greater than the standard risk. The potential risk attributable to home stool collection includes contamination of food, and spread of fecal oral organisms if appropriate hand washing is not performed.
b. Subject potential benefit i. The potential benefit to patients is resolution of abdominal pain symptoms
E. Informed Consent Process (Consent/Permission/Assent)
a. The principal investigator will ensure that the patient's parent/guardian is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. As all patients will be greater than assent age, assent will be obtained for all children enrolled in the study. Patients and the patient's parent/guardian will be given the opportunity to ask questions and allowed time to consider the information provided.
The patient/guardian's signed and dated informed consent as well as the patient's assent will be obtained before conducting any procedure or test specifically for the study.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Condition ICMJE||C. Difficile Infection|
|Intervention ICMJE||Drug: metronidazole
Metronidazole, 500 mg three times a for 10 days
Other Name: Flagyl
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Unknown status|
|Estimated Enrollment ICMJE||50|
|Completion Date||Not Provided|
|Estimated Primary Completion Date||December 2014 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
At time of Colonoscopy:
|Ages||7 Years to 21 Years (Child, Adult)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT01472978|
|Other Study ID Numbers ICMJE||C diff 101
WCHOB 101 ( Other Identifier: Women and Children's Hospital of Buffalo )
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Susan Baker, State University of New York at Buffalo|
|Study Sponsor ICMJE||State University of New York at Buffalo|
|Collaborators ICMJE||Not Provided|
|Investigators ICMJE||Not Provided|
|PRS Account||State University of New York at Buffalo|
|Verification Date||June 2012|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP